In Europe, market penetration of these drugs has varied widely from country to country, serving perhaps as an indication that merely being a cheaper substitute is not a passport to acceptance. However, these drugs certainly have a foothold abroad. Zarxio, while waiting on the wings of the US stage, is currently marketed as Zarzio in 60 other countries, according to Novartis, parent company of Sandoz. That cheaper biologics are needed in an age of soaring cancer costs is not a point that begs substantiation. It is what many would call a no-brainer. But getting to a place where Europe has already been for many a year, where biosimilars are widely used and accepted—increasingly so&ampmdash;seems likely to involve a process of battle and compromise that will continue long past this current Zarxio episode. Legislative debates over biosimilars are expected to play out in all 50 states. Read all about it in this month's Oncology Business Management.